Citius Pharmaceuticals, Inc. (CTXR)
| Market Cap | 17.35M +131.3% |
| Revenue (ttm) | 3.94M |
| Net Income | -35.89M |
| EPS | -2.46 |
| Shares Out | 27.11M |
| PE Ratio | n/a |
| Forward PE | 0.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 865,126 |
| Open | 0.6600 |
| Previous Close | 0.6541 |
| Day's Range | 0.6200 - 0.6609 |
| 52-Week Range | 0.5700 - 2.4800 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 6.00 (+837.5%) |
| Earnings Date | May 12, 2026 |
About CTXR
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and Nove... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CTXR stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 837.50% from the latest price.
News
Citius Oncology announces initial shipment of LYMPHIR to Europe
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through one of its regional distribution partners, marking an...
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets CRANFO...
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa...
Citius Pharmaceuticals announces $5M registered direct offering priced ATM
Citius Pharmaceuticals (CTXR) announced that it has entered into a definitive agreement for the purchase of an aggregate of 5,076,143 shares of its common stock at a purchase price of
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa...
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration CRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, ...
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available CRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius On...
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data of University of Pittsburgh-led t...
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response ...
Citius Pharmaceuticals receives $3.8M through NJEDA program
Citius Pharmaceuticals (CTXR) has received $3.8M in non-dilutive capital through New Jersey’s Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Progra...
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a bio...
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
Citius Pharmaceuticals (CTXR) reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned sub...
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
Q1 consolidated revenue was $3.9M, reflecting initial U.S. sales of Lymphir at Citius Oncology (CTOR). Cash and cash equivalents totaled $7.7M as of December 31, 2025.
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Onco...
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Phar...
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Third international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J., Feb. 11, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") ...
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct off...
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J. , Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "...
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J. , Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharm...
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a definitive agreement with a single healthcare-focused investor for the pu...
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL) CRANFORD, N.J. , Dec. 9, 2025 /PRNewswire/ -- Citius Onco...
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE LYMPHIR international availability extends to 1...
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
LYMPHIR now available nationwide CRANFORD, N.J. , Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc....
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J. , Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: C...
Citius Oncology to advance launch of Lymphir with Verix AI integration
Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced a deeper collaboration with Verix, a company in AI-powered commercial optimization technology for th...